Systemic therapy with pemigatinib and sintilimab followed by resection for recurrent FGFR-2-positive intrahepatic cholangiocarcinoma: a case report
BackgroundFibroblast growth factor receptor-2 (FGFR-2) mutations are frequently observed in intrahepatic cholangiocarcinoma (ICC). While FGFR2-targeted therapies are primarily studied in advanced ICC, this report presents a rare case of locally recurrent ICC treated with systemic therapy, leading to...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1527372/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850272902702694400 |
|---|---|
| author | Yuchen Yang Jingfeng Li Di Ma Fengjie Hao Weixia Li Jing Xie Lihan Qian Junqing Wang Yongjun Chen |
| author_facet | Yuchen Yang Jingfeng Li Di Ma Fengjie Hao Weixia Li Jing Xie Lihan Qian Junqing Wang Yongjun Chen |
| author_sort | Yuchen Yang |
| collection | DOAJ |
| description | BackgroundFibroblast growth factor receptor-2 (FGFR-2) mutations are frequently observed in intrahepatic cholangiocarcinoma (ICC). While FGFR2-targeted therapies are primarily studied in advanced ICC, this report presents a rare case of locally recurrent ICC treated with systemic therapy, leading to significant tumor regression and successful R0 resection.Case presentationA 51-year-old female underwent right posterior hepatectomy and cholecystectomy in 2018 for ICC. In August 2022, postoperative MRI revealed tumor recurrence near the hepatic vein, accompanied by intrahepatic bile duct dilation and a tumor thrombus. Given the tumor’s proximity to critical structures and confirmed FGFR-2 fusion, systemic therapy with pemigatinib and sintilimab was initiated. After four cycles, the tumor showed partial remission, with a reduction in the bile duct tumor thrombus. In May 2023, the patient underwent successful right hemi-hepatectomy. Postoperatively, she continued combination therapy without recurrence or metastasis for 19 months.ConclusionThis case highlights the efficacy of pemigatinib-based systemic therapy in achieving tumor regression and enabling curative resection in locally recurrent FGFR-2-positive ICC. The successful outcome underscores the potential of targeted therapies in managing recurrent ICC, warranting further investigation. |
| format | Article |
| id | doaj-art-b2ccef90054747af8f429335fb50d5e1 |
| institution | OA Journals |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-b2ccef90054747af8f429335fb50d5e12025-08-20T01:51:39ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-04-011510.3389/fonc.2025.15273721527372Systemic therapy with pemigatinib and sintilimab followed by resection for recurrent FGFR-2-positive intrahepatic cholangiocarcinoma: a case reportYuchen Yang0Jingfeng Li1Di Ma2Fengjie Hao3Weixia Li4Jing Xie5Lihan Qian6Junqing Wang7Yongjun Chen8Departement of General Surgery, Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, ChinaDepartement of General Surgery, Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, ChinaDepartement of General Surgery, Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, ChinaDepartement of General Surgery, Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, ChinaDepartment of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Pathology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, ChinaDepartement of General Surgery, Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, ChinaDepartement of General Surgery, Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, ChinaDepartement of General Surgery, Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, ChinaBackgroundFibroblast growth factor receptor-2 (FGFR-2) mutations are frequently observed in intrahepatic cholangiocarcinoma (ICC). While FGFR2-targeted therapies are primarily studied in advanced ICC, this report presents a rare case of locally recurrent ICC treated with systemic therapy, leading to significant tumor regression and successful R0 resection.Case presentationA 51-year-old female underwent right posterior hepatectomy and cholecystectomy in 2018 for ICC. In August 2022, postoperative MRI revealed tumor recurrence near the hepatic vein, accompanied by intrahepatic bile duct dilation and a tumor thrombus. Given the tumor’s proximity to critical structures and confirmed FGFR-2 fusion, systemic therapy with pemigatinib and sintilimab was initiated. After four cycles, the tumor showed partial remission, with a reduction in the bile duct tumor thrombus. In May 2023, the patient underwent successful right hemi-hepatectomy. Postoperatively, she continued combination therapy without recurrence or metastasis for 19 months.ConclusionThis case highlights the efficacy of pemigatinib-based systemic therapy in achieving tumor regression and enabling curative resection in locally recurrent FGFR-2-positive ICC. The successful outcome underscores the potential of targeted therapies in managing recurrent ICC, warranting further investigation.https://www.frontiersin.org/articles/10.3389/fonc.2025.1527372/fullintrahepatic cholangiocarcinomaFGFR-2systemic therapylocally advanced recurrencecase report |
| spellingShingle | Yuchen Yang Jingfeng Li Di Ma Fengjie Hao Weixia Li Jing Xie Lihan Qian Junqing Wang Yongjun Chen Systemic therapy with pemigatinib and sintilimab followed by resection for recurrent FGFR-2-positive intrahepatic cholangiocarcinoma: a case report Frontiers in Oncology intrahepatic cholangiocarcinoma FGFR-2 systemic therapy locally advanced recurrence case report |
| title | Systemic therapy with pemigatinib and sintilimab followed by resection for recurrent FGFR-2-positive intrahepatic cholangiocarcinoma: a case report |
| title_full | Systemic therapy with pemigatinib and sintilimab followed by resection for recurrent FGFR-2-positive intrahepatic cholangiocarcinoma: a case report |
| title_fullStr | Systemic therapy with pemigatinib and sintilimab followed by resection for recurrent FGFR-2-positive intrahepatic cholangiocarcinoma: a case report |
| title_full_unstemmed | Systemic therapy with pemigatinib and sintilimab followed by resection for recurrent FGFR-2-positive intrahepatic cholangiocarcinoma: a case report |
| title_short | Systemic therapy with pemigatinib and sintilimab followed by resection for recurrent FGFR-2-positive intrahepatic cholangiocarcinoma: a case report |
| title_sort | systemic therapy with pemigatinib and sintilimab followed by resection for recurrent fgfr 2 positive intrahepatic cholangiocarcinoma a case report |
| topic | intrahepatic cholangiocarcinoma FGFR-2 systemic therapy locally advanced recurrence case report |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1527372/full |
| work_keys_str_mv | AT yuchenyang systemictherapywithpemigatinibandsintilimabfollowedbyresectionforrecurrentfgfr2positiveintrahepaticcholangiocarcinomaacasereport AT jingfengli systemictherapywithpemigatinibandsintilimabfollowedbyresectionforrecurrentfgfr2positiveintrahepaticcholangiocarcinomaacasereport AT dima systemictherapywithpemigatinibandsintilimabfollowedbyresectionforrecurrentfgfr2positiveintrahepaticcholangiocarcinomaacasereport AT fengjiehao systemictherapywithpemigatinibandsintilimabfollowedbyresectionforrecurrentfgfr2positiveintrahepaticcholangiocarcinomaacasereport AT weixiali systemictherapywithpemigatinibandsintilimabfollowedbyresectionforrecurrentfgfr2positiveintrahepaticcholangiocarcinomaacasereport AT jingxie systemictherapywithpemigatinibandsintilimabfollowedbyresectionforrecurrentfgfr2positiveintrahepaticcholangiocarcinomaacasereport AT lihanqian systemictherapywithpemigatinibandsintilimabfollowedbyresectionforrecurrentfgfr2positiveintrahepaticcholangiocarcinomaacasereport AT junqingwang systemictherapywithpemigatinibandsintilimabfollowedbyresectionforrecurrentfgfr2positiveintrahepaticcholangiocarcinomaacasereport AT yongjunchen systemictherapywithpemigatinibandsintilimabfollowedbyresectionforrecurrentfgfr2positiveintrahepaticcholangiocarcinomaacasereport |